Generic name |
ambrisentan |
---|---|
Strength |
5 mg, 10 mg |
Form |
tablet |
Special Authority criteria |
Approval period |
---|---|
As monotherapy, for the treatment of World Health Organization (WHO)/New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH), in patients who have had an inadequate response and/or a contraindication to sildenafil. The usual dose of ambrisentan should be limited to a maximum of 10mg daily. |
1 year |